CN102000062B - Application of E ring bromine substituted silybin to preparing glycosidase inhibitors - Google Patents
Application of E ring bromine substituted silybin to preparing glycosidase inhibitors Download PDFInfo
- Publication number
- CN102000062B CN102000062B CN2010105218071A CN201010521807A CN102000062B CN 102000062 B CN102000062 B CN 102000062B CN 2010105218071 A CN2010105218071 A CN 2010105218071A CN 201010521807 A CN201010521807 A CN 201010521807A CN 102000062 B CN102000062 B CN 102000062B
- Authority
- CN
- China
- Prior art keywords
- alpha
- glucosidase
- glycosidase
- diabetes
- flavonolignans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of E ring bromine substituted silybin to preparing glycosidase inhibitors and in particular discloses application of E ring bromine substituted silybin ester-type flavonolignans or pharmaceutical salt thereof to preparing drugs for inhibiting alpha-glycosidase and preventing and treating type II diabetes. The flavonolignans has extremely obvious activity for inhibiting alpha-glycosidase and the intensity of activity of the flavonolignans for inhibiting alpha-glycosidase reaches 77.1% under the condition of 4mcg/ml concentration. The measured half-inhibitory concentration of the flavonolignans shows that the intensity of activity of the flavonolignans for inhibiting alpha-glycosidase is 32 times that of the positive control drug acarbose. The pharmacodynamics result shows that the flavonolignans or pharmaceutical salt thereof can be expected to be applied to preparing glycosidase inhibitors, especially the drugs for preventing and treating type II diabetes.
Description
Technical field
The present invention relates to medical technical field; Particularly; The present invention relates to a kind of E ring bromine substituted silybin ester type flavanolignan or its officinal salt be used for preparing suppress alpha-glucosidase, the control type ii diabetes also is the purposes of non-insulin-dependent diabetes mellitus medicine; This flavanolignan has the activity that suppresses alpha-glucosidase extremely significantly; Its inhibition activity intensity to alpha-glucosidase when 40 mcg/ml concentration has reached 77.1%; Show through measuring its half-inhibition concentration: the intensity of this flavanolignan's inhibition alpha-glucosidase is 32 times of positive control medicine acarbose; Therefore this chemical compound or its pharmaceutically useful salt, and the pharmaceutical composition that becomes with preparation allowable pharmaceutical excipients or preparing carriers can be expected and especially prevented and treated the purposes that type ii diabetes also is the non-insulin-dependent diabetes mellitus medicine as glycosidase inhibitor.
Background technology
Along with scientific and technological progress and growth in the living standard, in the world, the sickness rate of diabetes improves.According to statistics, diabetes occur on about 3% the person, and whole world patient's total number of persons surpasses 100,012,000, causes the heavy losses of national economy.
Diabetes are clinical common endocrine metabolism property diseases.Doctor trained in Western medicine thinks that diabetic can be divided into two kinds: promptly (or claim insulin-dependent, IDDM) (or title non-insulin-depending type, NIDDM), wherein type ii diabetes is wider, endangers bigger with type ii diabetes for type i diabetes.China's diabetics has more than 2,000 ten thousand, and wherein nearly 90% is type ii diabetes.Along with the change of life style, dietary habit, and the development of science and technology and medical level, detecting factors such as the early diabetes level improves constantly, countries in the world life expectancy and onset diabetes rate are all improving constantly.This disease characteristics multiple, rejuvenation occurred especially in China, has caused very large loss for the national economy and productivity development.
The oral drugs of treatment type ii diabetes have sulfonylurea, biguanides, alpha-glucosidase inhibitor class and insulin sensitizer four big kinds at present, but each tool pluses and minuses.Alpha-glucosidase inhibitor is the research and development theory of the new treatment NIDDM that begins to rise the seventies in last century.This is the supplement therapy means of the invalid type ii diabetes of treatment sulfa drugs secondary.Bibliographical information uses competitive alpha-glucosidase inhibitor, can postpone conversion and the absorptions of saccharide compound in digestive tract such as starch, sucrose, alleviates the kidney burden; Suppress after meal that blood glucose sharply rises, make blood sugar concentration in one day, change fluctuating margin and reduce.This is Fructus Vitis viniferae IGR impaired glucose tolerance (IGT) stage especially of effectively suppressing diabetics early stage, many as yet not the potential patients of diabetes of morbidity still be in the middle of this stage.The Alpha-glucosidase inhibitor acarbose (acarbose) of Bayer A.G's development went on the market in Germany in nineteen ninety, had become a plurality of countries at present, comprised China, a line medication of treatment type ii diabetes, and its commodity are called acarbose.Type ii diabetes research in policy group in the Asian-Pacific area provided the treatment guide in 2005, and (inhibitor of α-glucosidase) is as the first-selected medication that reduces post-prandial glycemia with alpha-Glucosidase.Various countries launch keen competition to new Alpha-glucosidase inhibitor and hypoglycemic medicine.The alpha-glucosidase inhibitor voglibose (voglibose) of Japan's exploitation is also in listing in 1994.Yet it occupies the competition that high price will receive the similar medicine of novel cheap novelty.Just the alpha-glucosidase inhibitor in clinical trial also has miglitol (miglitol), emigliate etc.It should be noted that: the untoward reaction of the increasing alpha-glucosidase inhibitor that gone on the market also claims to the new inhibitor that updates.Skin allergies such as gastrointestinal side effect, erythema, erythra and urticaria; The severe hepatic dysfunction of jaundice, GOT, GPT rising etc.; Cardiac system risk etc. all be such the treatment blind area of marketed drug [referring to Li Zhongfen, " adverse effect journal the 4th phase of calendar year 2001; Yang Xiaohui etc., " Chinese pharmacovigilance " 1 phase in 2009; Deng bibliographical information].Thereby develop actively is imitated more by force, the novel abiotic bases Alpha-glucosidase inhibitor of safety has urgency and necessity.
Based on this purpose; The inventor once accomplished the research of multinomial development of new alpha-glucosidase inhibitor class natural product and structure of modification derivant thereof; And find the chemical compound of multiple inhibition alpha-glucosidase activity; Thereby explain that it is feasible [referring to " application of arjunolic acid in the preparation glycosidase inhibitor " from natural product and synthesis of derivatives thereof, filtering out novelty hypoglycemic medicine that strong effect suppresses alpha-glucosidase inhibitor; Zhang Rongping, Dou Hui, Zhao Yu, Wu Xiumei etc., CN 101416970; " application of belulinic acid Betulinic acid in the preparation glycosidase inhibitor ", Zheng Hanqi, Dou Hui, Zhang Rongping, Zhao Yu, Wu Xiumei etc., CN 101416971; " the substituted ramification of pentacycle triterpene of A ring polyoxyization ", Zhao Yu, Feng Juhong, Wu Xiumei, Bai Hua, the uncommon spy of Yue Ashi Stoker, CN 101117349; " the substituted pentacyclic triterpene of A ring and C ring both polyoxyization ", Zhao Yu, Chen Haiyong, Zheng Hanqi, Wu Xiumei, Bai Hua, the uncommon spy of Yue Ashi Stoker, CN 101117348].Undoubtedly, it is very necessary and urgent continuing from natural product and structure of modification derivant thereof, to seek the lead compound that can suppress alpha-Glucosidase.
In addition, protecting the liver in the kind new medicine exploitation problem of inventor's long-term accumulation, a large amount of clinically a kind of natural drugs that use have been related to: promptly be present in the silymarin in the seed of feverfew Herba Silybi mariani.Herba Silybi mariani is extensive use clinically, its commodity Legalon by name on market
TMGrand or the Flavobion of sharp liver
TM, its representative compound surely belongs to flavanolignan's silibinin.Flavone lignin compound belongs to weedtree quality class, is one type of natural product of and a part flavone be combined into plain by a part phenylpropyl alcohol.Silibinin content is maximum in the Herba Silybi mariani, and activity is also the highest.This medicine effect mainly contain following some: (one) free radical resisting is active: silymarin has protective effect for the hepatic injury that is caused by carbon tetrachloride, galactosamine, alcohols and other hepatotoxin.People such as nineteen ninety Lotteron have reported in the Mouse Liver microsome; Silymarin can reduce external lipid peroxidation that is caused by the carbon tetrachloride metabolism and the peroxidation that is caused separately by reduced coenzyme, and these show that all silymarin is the chain interruption antioxidant or is free radical scavenger.(2) protection liver plasma membrane: keep flowability of cell membranes through the anti peroxidation of lipid reaction, the protection liver plasma membrane.Can also block combining of special receptor on mycotoxin phalloidine and α-amanitin etc. and the hepatocyte, suppress it, interrupt its liver sausage circulation, thereby the enhance hepatocyte film be for the resistance of multiple damage factor hepatocellular attack and transmembrane transport.(3) promote hepatocellular reparation and regeneration: silibinin can combine with ER after getting into cell; And make it to activate; Activated receptors can enhance hepatocyte nuclear RNA polymerase 1 activity, rna transcription is strengthened, promote enzyme and proteinic synthetic; And promote the synthetic of DNA indirectly, help hepatocellular reparation and regeneration.(4) antitumor action: various active oxygens can form 8-hydroxyl guanine by the oxidation guanine, cause DNA damage, and then cause tumor, and silibinin has also shown the effect of prevention and treatment tumor as an effective free radical resisting material.This medical instrument of the clinical trial certificate of three more than ten years has definite curative effect and hypotoxicity (to consult Flora K. etc., Am.J.Gastroenterol, 1998,93,139-143; SallerR. etc., Drugs, 2001,61 (14), 2035-2063;
R. etc.; Curr.Med.Chem.; 2007; 14,315-338;
Z. etc.; Phytother.Res.; 2003; 17,524-530;
R. etc.; Bioorg.Med.Chem.; 2004; 12,5677-5687; Varga Z. etc., Phytothe.Res., 2001,15,608-612; Singh R.P. etc., Curr.CancerDrug Tar., 2004,4,1-11).Therefore; The flavone lignin chemical compound that with the silibinin is representative has caused increasing concern; In the period of 2006-2009, prepare and a plurality of serial silibinin analog derivative reported also has obvious antioxidation activity (Yang Leixiang, Zhao Yu etc., " Design, synthesis and examination of neuron protectiveproperties of alkenylated and amidated dehydro-silybin derivatives " like the inventor; Journal of Medicinal Chemistry; 2009,52 (23), 7732-7752; Wang Feng, Zhao Yu etc.; " Preparation of C-23 esterified silybin derivatives and evaluation oftheir lipid peroxidation inhibitory and DNA protective properties "; Bioorganic and Medicinal Chemistry; 2009,17 (17), 6380-6389; Yang Leixiang, Zhao Yu etc.; " Synthesis and antioxidant properties evaluation of novelsilybin analogues ", Journal of Enzyme Inhibition and MedicinalChemistry, 2006; 21 (4), 399-404; Or the like).In the above-mentioned article of inventor report, A ring, B ring, E ring and 23 substituted flavanolignan compounds of a plurality of series that design and synthesize out through the inventor all demonstrate strong effect and catch the activity of DPPH free radical and ultra-oxygen anion free radical, antioxidant activity and protection PC12 cell activity.But obvious: above-mentioned research only concentrates on antioxidation and the cytoprotection of studying the silibinin flavonolignan.
Though with silibinin and dehydro-silibinin is that flavanolignan's chemical compound of representative has the antioxidation curative effect of the above, yet do not see that it is used to suppress the report of glycosidase, treatment diabetes aspect.Flavanolignan's compounds for treating type ii diabetes; Especially its new purposes that is used to suppress alpha-glucosidase is effectively developed as yet; So from flavanolignan, seek to suppress the reactive compound of alpha-glucosidase, also being about to flavanolignan's structure of modification, to make it have treatment type ii diabetes effect be a brand-new field.From wherein finding the efficient lead compound challenge that forefathers did not attempt especially that suppresses alpha-glucosidase.In order to explore this field; Our design has also prepared and silibinin structure a kind of new flavanolignan's derivant of difference to some extent; The E ring module that also is about to former silibinin transform 3-bromo-4-hydroxy-5-methyl oxygen base substitute mode as; Change whole molecular conjugation scope and conjugation intensity, introduce halogen bromine atoms and new hydrogen bond receptor or donor simultaneously.So design can generate the plain flavanone alcohol compound (also being one type of novel flavanolignan chemical compound) of one type of novel wooden that the new spatial structure is different from silibinin; In the hope of finding to suppress flavanolignan's lead compound of alpha-glucosidase, has the novelty medicine that can suppress alpha-glucosaccharase enzyme treatment NIDDM thereby it is developed further into.Accomplish the present invention in view of the above.
Summary of the invention
The E ring substituted silybin ester of bromine or its officinal salt that the purpose of this invention is to provide structure shown in the formula (1) are used for the purposes that preparation suppresses alpha-glucosidase, treatment NIDDM disease medicament;
The name of formula (1) chemical compound is called: (±)-2-[2,3-dihydro-3-(3-bromo-4-hydroxy-5-methyl oxygen base phenyl)-2-methylol-1,4-benzodioxane-6-]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
Another object of the present invention has provided the method for the substituted silybin esters flavonol of the E ring bromine lignin chemical compound shown in a kind of preparation formula (1), and the synthesis route characteristic of this method is:
Wherein, OEt refers to ethyoxyl; R
1It is bromine atoms; R
2It is methoxyl group.
Specifically realize through following steps: the 3-bromo-4-hydroxy-5-methyl substituted benzaldehyde of oxygen base (I-a) obtains the 3-bromo-4-hydroxy-5-methyl substituted ethyl cinnamate of oxygen base (I-b) with the phosphorus ylide condensation in chloroformic solution; In anhydrous tetrahydro furan, it is substituted to hydroxyl cinnamyl alcohol (I-c) to obtain 3-bromo-4-hydroxy-5-methyl oxygen base with lithium aluminium hydride-alchlor in the room temperature reduction.Dihydroquercetin (II) and I-c are oxidant with the Disilver carbonate in anhydrous benzene and anhydrous propanone mixed solvent, obtain the substituted silibinin analog of E ring bromine shown in the formula (1) through oxidative coupling.
Another object of the present invention has provided a kind of pharmaceutical composition that is used to suppress alpha-glucosidase, treatment NIDDM disease, it is characterized by the perhaps mixture formed of its officinal salt and pharmaceutically acceptable auxiliaries of the formula as active component (1) chemical compound of treat effective dose by containing.Its pharmaceutical dosage form can be that tablet, capsule, injection, aerosol, suppository, membrane, drop pill, paster agent, subcutaneous planting bury agent, externally-applied liniment, oral liquid or ointment, can also adopt the known controlled release of modern pharmaceutical circle or slow release formulation or nanometer formulation.
The E ring bromine substituted silybin ester type flavanolignan (1) of inventor's design compares with natural flavone Lignanoids compounds silibinin; Characteristic with differentiation on many structures and the physico-chemical property comprises that speciality such as its hydrophobicity, armaticity, Gibbs free energy, hydrogen bond receptor, electrical, intermolecular Van der Waals force and 3D conformation, direction of extension, molecule center of gravity, electrical distribution center all have obviously different with silibinin; And chemical compound (1) molecular weight ratio silibinin has increased 78 mass units.The ligand-receptor that above-mentioned characteristic has all determined the three-dimensional conformation of chemical compound shown in the formula (1) to combine with the 3d space structure of alpha-glucosidase combines complex form and combination all possibly produce bigger difference; Its binding site and binding pattern, its combination free energy etc. all can produce bigger change, thereby possibly suppress aspect the alpha-glucosidase beyond thought effect arranged.
We have tested the growth inhibited effect of this chemical compound to alpha-glucosidase; Result of the test is found: this flavanolignan has the activity that suppresses alpha-glucosidase extremely significantly, and its inhibition activity intensity to alpha-glucosidase when 40 mcg/ml concentration has reached 77.1%.Show through measuring its half-inhibition concentration: the intensity of this flavanolignan's inhibition alpha-glucosidase is 32 times of positive control medicine acarbose.Above pharmacodynamic result explanation formula (1) chemical compound has beyond thought inhibition alpha-glucosidase effect, thereby can expect that this flavanolignan or its officinal salt can be expected especially prevents and treats the purposes that type ii diabetes also is the non-insulin-dependent diabetes mellitus medicine as glycosidase inhibitor.
In sum; Uniqueness on this flavanolignan's existing structure that we prepare; The novelty that suppresses glycosidase effect aspect research is arranged again; And in hypoglycemic activity test, found the activity of uncommon inhibition alpha-glucosidase to be expected to become the lead compound that suppresses alpha-glucosidase and treatment NIDDM.Up to the present, still there is not the relevant report that suppresses the alpha-glucosidase medicine about this compounds for treating NIDDM disease and preparation.Flavanolignan's formula (1) chemical compound is imitated by force for alpha-glucosidase and is suppressed to belong to beyond thought discovery, and definite originality is arranged.
Usefulness of the present invention is: the substituted silybin ester type of the ring bromine of the E shown in the discoverable type (1) flavanolignan has the effect of extremely strong effect inhibition alpha-glucosidase and has the patent medicine potentiality aspect the control NIDDM disease first, and the innovative hypoglycemic medicine that becomes treatment NIDDM disease original new drug, exploitation inhibition alpha-glucosidase for exploitation provides new material base.Have potential huge social benefit and economic benefit.The present invention's characteristics again is: the present invention's synthetic starting material convenient sources, and its preparation method is simple, and cost is low, pollutes for a short time, is beneficial to the large-scale production under the energy-saving and emission-reduction condition.Industrialization prospect is very clear and definite.
The specific embodiment
The inventor is simply synthetic through multistep, and obtains flavanolignan's class reactive compound that this can effectively suppress alpha-glucosidase activity through the chromatography means, derives its chemical constitution through integration analysis such as mass spectrum and NMR spectrums again.The inventor finds that formula (1) chemical compound has significant inhibitory effect to alpha-glucosidase.Therefore; According to the inventor's research, the inventor design and synthetic formula (1) shown in E ring bromine substituted silybin flavonolignan chemical compound can be used to prepare the medicine that suppresses alpha-glucosidase, control NIDDM disease and be used to treat type ii diabetes.
In order to understand essence of the present invention better, use the preparation of formula (1) chemical compound and the result that the inhibitory action of alpha-glucosidase is tested thereof below respectively, its new purposes in pharmaceutical field is described.Embodiment has provided partial synthesis, the structure of formula (1) chemical compound and has identified and activity data.Mandatory declaration, embodiments of the invention are to be used to explain the present invention rather than limitation of the present invention.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the present invention and requires the scope protected.
Embodiment 1:Formula (1) (±)-2-[2,3-dihydro-3-(3-bromo-4-hydroxy-5-methyl oxygen base phenyl)-2-methylol-1,4-benzodioxane-6-]-2,3-dihydro-3,5, the preparation of 7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone
1.1 instrument and reagent:
Ultraviolet spectra is measured with Shimadzu UV-240 ultraviolet spectrophotometer; Proton nmr spectra
1H-NMR measures (tetramethylsilane ether TMS is interior mark) by INOVA type NMR spectrometer with superconducting magnet (VARIAN INOVA-400MHz); Electrospray Mass Spectrometry ESI-MS is measured by BrukerEsquire 3000+ mass spectrograph, and column chromatography is produced by Haiyang Chemical Plant, Qingdao with silica GF254 (10-40 order) with silica gel (100-200,200-300 and 300-400 order) and thin layer chromatography; Agents useful for same is analytical pure; Thin layer preparative chromatography (PTLC) is with the aluminium foil silica gel plate of Merck company; Column chromatography adopts Sweden Amersham Pharmacia Biotech AB Company products with polydextran gel Sephadex LH-20; Reverse phase silica gel RP-18 adopts the Chromatorex product of Japanese Fuji Silysia Chemical company; MCI is a Mitsubishi chemical company product, and thin plate (TLC) detects with 254 and the uviol lamp of 365nm; Developer is with iodine vapor, 10% sulphuric acid-ethanol and phosphorus molybdenum acid solution.
1.2 the preparation of key intermediate I-c (3-bromo-4-hydroxy-5-methyl oxygen base is substituted to the hydroxyl cinnamyl alcohol):
In drying, add 0.11 gram lithium aluminium hydride (3 mM) in the reaction bulb of nitrogen protection, 0.13 gram aluminum chloride (1 mM) slowly adds 10 milliliters of anhydrous tetrahydro furans, is stirred to no gas and emits; 5 milliliters of anhydrous tetrahydrofuran solutions that will be dissolved with 0.3 gram 3-bromo-4-hydroxy-5-methyl oxygen base ethyl cinnamate (1 mM, self-control) slowly add in the reactant, in stirring at room after 1 hour with 20% hcl acidifying to pH=2; Filter; Dried over mgso is filtered, concentrate yellow oil; Get light yellow solid 0.19 gram, yield 73% through column chromatography.Rf (petroleum ether: ethyl acetate=3: 1): 0.12; Proton nmr spectra
1HNMR (400MHz, deuterochloroform) δ: 3.85 (unimodal, 3H, OCH
3), 4.49 (bimodal, J=5.4Hz, 2H, H-9), 6.25 (the dt peak, J=5.4,16.0Hz, 1H, H-8), 6.44 (bimodal, J=16.0Hz, 1H, H-7), 6.97 (unimodal, 1H, H-2), 7.08 (s, 1H, H-6); Electrospray Mass Spectrometry ESI-MS:m/z 257 [M-H]
+
1.3 the preparation of chemical compound (1)
In the reaction bulb of drying nitrogen protection, drop into 80 milligrams of dihydroquercetins (this chamber self-control, purity is greater than 98% (HPLC)), 103 milligrams of 3-bromo-4-hydroxy-5-methyl oxygen base cinnamyl alcohol and 88 milligrams of Disilver carbonates; Inject 5 milliliters of anhydrous propanones and 20 milliliters of anhydrous benzene; Insulation is 3.5 hours between 55-60 ℃, filters, and mother solution concentrates; Column chromatography (chloroform: ethyl acetate: formic acid=25: 1: 0.25) separate 52 milligrams of buff powders, yield 35%.
(±)-2-[2,3-dihydro-3-(3-bromo-4-hydroxy-5-methyl oxygen base phenyl)-2-methylol-1,4-benzodioxane-6-]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone: R
f(chloroform: ethanol=20: 1): 0.16; Proton nmr spectra
1H NMR (400MHz, deuterated acetone) δ: 3.42 (multiplet, 1H, H-23a), 3.69 (multiplet, 1H, H-23b), 3.78 (unimodal, 3H, OCH
3), 4.04 (multiplet, 1H, H-10), 4.54 (double doublet, J=6.0,12.0Hz; H-3), 4.91 (bimodal, J=8.0Hz, 1H, H-11), 4.99 (bimodal, J=12.0Hz; 1H, H-2), 5.86 (unimodal, 1H, H-6), 5.88 (unimodal, 1H; H-8), 6.83-7.15 (multiplet, 5H, Ar-H), 11.56 (unimodal, 1H, 5-OH); Electrospray Mass Spectrometry ESI-MS:m/z 559 [M-H]
+
Embodiment 2: chemical compound (1) (±)-2-[2,3-dihydro-3-(3-bromo-4-hydroxy-5-methyl oxygen base phenyl)-2-methylol-1,4-benzodioxane-6-]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone detects the inhibition of alpha-glucosidase is active
2.1 instrument and reagent
2.1.1 experimental apparatus
ELIASA: ELISA plate reader (Bio-Tek Instruments, USA)
2.1.2 reagent
Alpha-glucosidase is α-D-glucosidase (Sigma, a 500U/ milliliter); 4-nitrophenols-α-D-pyranglucoside (PNPG, Merck), reductive glutathione (worker is given birth in Shanghai), acarbose is acarbose (Bayer HealthCare Co, Beijing).
2.2 method of testing
Chemical compound is measured the inhibitory action of alpha-glucosidase and is adopted colorimetry.Add phosphate buffer (67 mMs/liter, pH 6.8,170 microlitres) in the sample well, reduced form glutathione (1 mg/ml; 5 microlitres), α-D-glucosidase (being diluted to the 0.2U/ milliliter with phosphate buffer, 25 microlitres), chemical compound (1) dissolves with dimethyl sulfoxine; With the phosphate buffer dilution, every hole 25 microlitres, making its final concentration is 0.04 mg/ml, 0.004 mg/ml; 0.0004 mg/ml adds substrate 4-nitrophenols-α-D-pyranglucoside (23.2 mMs/liter, 25 microlitres), 37 ℃ at last; Behind the water-bath 15 minutes, add sodium carbonate (1 mol, 50 microlitres) cessation reaction, in the colorimetric determination of 405nm wavelength.Tris-HCl buffer with equal volume in the blank well replaces substrate.Add and the isocyatic dimethyl sulfoxine of chemical compound in the solvent control hole.The chemical compound suppression ratio is calculated with contrast OD value for blank by sample OD value.Sample is to the half-inhibition concentration (IC of alpha-glucosidase
50) obtain by dose effect curve.
2.3 result of the test is as shown in the table:
Table 1
2.4 experiment conclusion
Alpha-glucosidase be in the alpha-glucosidase inhibitor drug screening index property testing enzyme, many medicines are based on becomes hypoglycemic medicine to the alpha-glucosidase competitive inhibition.This experiment shows that the substituted silybin ester of E ring bromine of structure shown in the formula (1) has the effect that strong effect suppresses alpha-glucosidase, and its inhibition activity intensity to alpha-glucosidase when 40 mcg/ml concentration has reached 77.1%.Show through measuring its half-inhibition concentration: the intensity of this flavanolignan's inhibition alpha-glucosidase is 32 times of positive control medicine acarbose; Thereby have very strong potentiality to be exploited of imitating, might further develop becomes new treatment type ii diabetes medication.
When above-mentioned description elaboration was of the present invention, the purpose that embodiment is provided simultaneously was to illustrate actual mechanical process of the present invention and meaning of the present invention.In the time of in getting into claim of the present invention and its equivalent scope, practical application of the present invention comprises all general variations, cooperates, or improves.
Claims (2)
1. the E ring substituted silybin ester of bromine or the purposes of its officinal salt in the medicine of preparation control type ii diabetes that have structure shown in the formula (1);
The name of formula (1) chemical compound is called: (±)-2-[2,3-dihydro-3-(3-bromo-4-hydroxy-5-methyl oxygen base phenyl)-2-methylol-1,4-benzodioxane-6-]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
2. the E ring substituted silybin ester of bromine or the application of its officinal salt in the hypoglycemic medicine of preparation inhibition alpha-glucosidase that have structure shown in the formula (1);
The name of formula (1) chemical compound is called: (±)-2-[2,3-dihydro-3-(3-bromo-4-hydroxy-5-methyl oxygen base phenyl)-2-methylol-1,4-benzodioxane-6-]-2,3-dihydro-3,5,7-trihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105218071A CN102000062B (en) | 2010-10-27 | 2010-10-27 | Application of E ring bromine substituted silybin to preparing glycosidase inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105218071A CN102000062B (en) | 2010-10-27 | 2010-10-27 | Application of E ring bromine substituted silybin to preparing glycosidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102000062A CN102000062A (en) | 2011-04-06 |
| CN102000062B true CN102000062B (en) | 2012-08-22 |
Family
ID=43807932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105218071A Expired - Fee Related CN102000062B (en) | 2010-10-27 | 2010-10-27 | Application of E ring bromine substituted silybin to preparing glycosidase inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102000062B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829094A (en) * | 2010-05-25 | 2010-09-15 | 大理学院 | Application of ring E bromine substituted silybin in preparing medicaments for treating viral hepatitis B |
-
2010
- 2010-10-27 CN CN2010105218071A patent/CN102000062B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829094A (en) * | 2010-05-25 | 2010-09-15 | 大理学院 | Application of ring E bromine substituted silybin in preparing medicaments for treating viral hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102000062A (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lam et al. | α-Glucosidase inhibitors from the seeds of Syagrus romanzoffiana | |
| EP1559703B1 (en) | A natural compound useful for treating diabetes, its preparation and use | |
| CN101966175A (en) | Application of dehydroabietic silybin in preparing glycosidase inhibitors | |
| CN102000059B (en) | Medicinal application of querecetin dipolymer flavonoids to preparation of glycosidase enzyme inhibitors | |
| CN102000061B (en) | Medicinal application of nitrobenzoyl silybin in preparation of glycosidase inhibitor | |
| CN102000057B (en) | Application of 4-cinnamoyl chloride substituted silybin in preparing glycosidase inhibitors | |
| CN101966174B (en) | Pharmaceutical application of p-bromocinnamoyl silybin to preparing glycosidase inhibitors | |
| CN102000062B (en) | Application of E ring bromine substituted silybin to preparing glycosidase inhibitors | |
| CN102000060B (en) | Application of E ring iodine substituted silybin to preparing glycosidase inhibitors | |
| CN102018701B (en) | Pharmaceutical application of angle flavonol lignans to preparing glucosidase inhibitors | |
| CN102000058B (en) | Application of B/E ring changed silybin in preparing glycosidase inhibitors | |
| CN102731597A (en) | Abelmoschus manihot extract and novel application of chemical components thereof | |
| CN101966173B (en) | Medicinal use of dinitrobenzoylsilybin for preparing glycosidase inhibitor | |
| CN102000063B (en) | Application of E ring benzyloxy substituted silybin in preparing glycosidase inhibitors | |
| CN113004299B (en) | Xanthone compound in mangosteen bark for reducing postprandial blood sugar, and extraction method and application thereof | |
| CN102000056B (en) | Pharmaceutical application of B ring methoxy substituted silybin in preparing glycosidase inhibitors | |
| CN102000064B (en) | Medicinal application of flavanonol lignan in preparation glycosidase inhibitors | |
| CN101829097A (en) | Application of dehydrogenation silybin in preparation of medicament for treating virus hepatitis B | |
| CN103739653A (en) | Novel 23-oleanolic acid compound as well as preparation method and application of compound in preparation of glycosidase inhibitor medicine | |
| CN101829094B (en) | Application of ring E bromine substituted silybin in preparing medicaments for treating viral hepatitis B | |
| CN104083348A (en) | Applications of four kaurane diterpene compounds in preparation of glycosidase inhibitor medicines | |
| CN101829090A (en) | Application of diamine formyl dehydrogenated silybin serving as medicament for curing viral hepatitis B | |
| CN101912387B (en) | Application of benzyl-containing flavonoid lignan in preparation of medicament for treating hepatitis B | |
| CN102766109B (en) | 2,3-diaryl thiazolidine-4-one/-thioketone compounds, oxides thereof and use thereof | |
| CN100525776C (en) | Application of peracetyl pueraria in preparation of medicine for treating blood deficient cerebrovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 Termination date: 20131027 |